July 11, 2024 01:39 PM EDT
Financing
Diagnostics

Il­lu­mi­na com­peti­tor El­e­ment Bio­sciences rais­es $277M in Se­ries D

Jared Whitlock

Features Editor

El­e­ment Bio­sciences has raised an ad­di­tion­al $277 mil­lion in pri­vate fi­nanc­ing to sup­port com­mer­cial­iza­tion of its bench­top DNA se­quencer and an in­stru­ment launch as the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times